Pharmaron Beijing (03759) reported its performance for 2025, with a net profit attributable to shareholders of 1.664 billion yuan, a decrease of 7.2% year-on-year.

Pharmaron Beijing (03759) released its annual performance as of December 31, 2025, with revenue of 14.095 billion yuan, a year-on-year increase of 14.8%; the net profit attributable to the parent company was 1.664 billion yuan, a year-on-year decrease of 7.2%; basic earnings per share were 0.9443 yuan, and a final dividend of 2.0 yuan (including tax) per 10 shares is proposed. During the reporting period, the company's laboratory services achieved operating income of 8.1589 billion yuan, an increase of 15.8% compared to the same period last year; the gross profit margin for 2025 was 44.7%, an increase of 0.3 percentage points from the previous year; new signed orders for the year increased by approximately 12%. In 2025, the company expanded several strategic partnerships, made breakthrough progress in large-scale collaborative projects, and achieved rapid development in the research and development of new molecular drug types with its disciplinary advantages and technological accumulation. During the reporting period, the proportion of biological sciences in the company's laboratory services revenue exceeded 56%. As of December 31, 2025, the company had 11,776 employees in its laboratory services, including over 7,100 laboratory chemists, positioning the company as a leading laboratory chemistry service team globally in terms of scale and experience. The company continues to support global innovative drug research and development, with the laboratory services team participating in 887 drug discovery projects for global innovative drugs during the reporting period.